# Filana Therapeutics, Inc > Clarifo company profile — qualitative business description generated from > the company's filings. Financial statements, charts and ratios are > available on Clarifo (https://www.clarifo.com/fi/companies/Filana Therapeutics, Inc). ## Overview Filana Therapeutics, Inc. is a clinical-stage biotechnology company based in Austin, Texas, focused on developing therapies for central nervous system disorders. Its lead program is simufilam, an oral small-molecule candidate being advanced for TSC-related epilepsy after the company discontinued its Alzheimer’s disease program in 2025. ## Products & services • Simufilam, oral small-molecule drug candidate for TSC-related epilepsy • Research-stage CNS drug discovery and development programs • Scientific publication and academic collaboration activities • Out-licensed / partnered development opportunities for future products - **Lead therapeutic candidate** (90%) — Simufilam, the company's proprietary oral small-molecule candidate being developed for CNS disorders, especially TSC-related epilepsy. - **Early-stage research programs** (5%) — Discovery and exploratory work to identify new indications and additional product candidates supported by experimental evidence. - **Collaborative development activities** (5%) — Research and development work performed with universities, CROs, CDMOs, and other partners. - Simufilam for TSC-related epilepsy - CNS disorder drug discovery and development - Clinical proof-of-concept studies - Academic and collaborative research programs - Potential licensing and royalty-based commercialization ## Customers Filana does not currently sell approved products, so its near-term 'customers' are mainly regulators, clinical investigators, academic collaborators, and contract service providers that enable development. If approved in the future, the end customers would be physicians, patients, and payors in the CNS and epilepsy markets. - **Regulators and clinical oversight bodies** (primary) — The company depends on FDA review, clinical hold resolution, and eventual marketing approval to advance simufilam. - **Research and development partners** (primary) — Universities, academic collaborators, CROs, CDMOs, and clinical sites that perform outsourced studies and formulation work. - **Future prescribers and patients** (secondary) — Neurologists, physicians, and patients in TSC-related epilepsy and other CNS indications who would use the drug if approved. - **Future payors and distributors** (secondary) — Commercial partners and reimbursement stakeholders that would support access, distribution, and market adoption after approval. - FDA and other regulators for clinical hold and approval decisions - Academic collaborators supporting discovery and translational research - CROs, CDMOs, and clinical sites running outsourced studies - Physicians and neurologists if simufilam is commercialized - Patients with TSC-related epilepsy and other CNS disorders - Payors that would influence adoption after approval ## Geography Filana is headquartered in Austin, Texas and operates primarily from the United States. Its development footprint is global through patents, academic collaborations, and outsourced clinical and manufacturing partners, with intellectual property coverage mentioned in the U.S., Europe, Australia, Israel, Canada, Japan, and China. - Headquartered in Austin, Texas - Core operations and management are U.S.-based - Clinical and preclinical work is outsourced to third parties - Patent coverage spans the U.S., Europe, Japan, China, Canada, and Australia - Future commercialization could require U.S. and international market access ## Strategy The company is narrowing its focus to simufilam and TSC-related epilepsy after ending its Alzheimer’s program. Its strategy is to resolve the FDA clinical hold, generate proof-of-concept data, and preserve optionality through patents, collaborations, and potential licensing. - **Lift the clinical hold and restart development** (short-term) — Clinical progress is blocked until the FDA hold is addressed, making this the key near-term value driver. - **Build evidence for TSC-related epilepsy** (medium-term) — Positive clinical data would validate the mechanism and support future regulatory and partnering discussions. - **Maintain capital efficiency through outsourcing** (short-term) — The company has limited infrastructure and must conserve cash while advancing a high-risk pipeline. - **Protect and expand intellectual property** (medium-term) — Patent coverage is central to future partnering leverage and any eventual commercialization value. - Resolve the FDA clinical hold on simufilam - Advance TSC-related epilepsy into proof-of-concept studies - Use outsourced R&D to keep the company lean - Expand patent protection across key markets - Pursue collaborations or licensing if development succeeds ## Risks Filana is a pre-revenue biotech with a single lead program, so its value depends heavily on clinical, regulatory, and financing outcomes. The company also faces elevated legal, supply-chain, cybersecurity, and execution risks because it outsources much of its development work and remains under a clinical hold. - **FDA clinical hold on simufilam** [critical] — The company cannot progress its TSC-related epilepsy program until the hold is lifted, directly affecting development timelines and value creation. - **Single-asset pipeline concentration** [high] — Most R&D is focused on simufilam, so any clinical or regulatory setback would have an outsized impact on the company. - **Dependence on third-party CROs, CDMOs, and clinical sites** [high] — The company outsources key development functions, so partner failures can delay studies, raise costs, or impair product quality. - **Legal proceedings and government inquiries** [high] — Management discloses ongoing claims and inquiries, which can create direct costs and distract management. - **Cybersecurity and data protection** [medium] — Clinical and IP data are sensitive, and breaches could disrupt operations or expose proprietary information. - **Financing risk and cash burn** [high] — The company has no product revenue and expects significant future cash needs, increasing dilution or going-concern pressure if capital markets tighten. - FDA clinical hold could delay or prevent simufilam development - Single-program concentration increases binary trial risk - Outsourced supply and manufacturing can disrupt timelines - Legal proceedings and government inquiries may create costs - Cash burn may require future financing on unfavorable terms - Cybersecurity or data breaches could disrupt trials and IP ## Accounting The most important accounting issues are R&D expense timing, stock-based compensation, and contingent liabilities from legal and regulatory matters. Because the company is pre-revenue and clinical-stage, small changes in trial timing, outsourcing activity, or accrual judgments can materially affect reported losses and comparability. - **Research and development expense recognition** — Period-to-period operating loss can swing with trial activity and outsourcing spend - **Stock-based compensation** — Can materially increase reported R&D and G&A expense - **Legal contingencies and accruals** — Could affect liabilities and earnings if estimates change - **No revenue recognition yet** — Current statements are driven by expenses rather than operating revenue - R&D expense timing depends on clinical and preclinical activity - Outsourced trial and CDMO costs can shift period-to-period - Stock-based compensation affects operating loss materially - Legal contingencies require judgment on accruals - No product revenue yet, so expense recognition drives results --- *Last updated: 2026-09-24T11:28:18.065303+00:00*